A phase 1/2 study of EP0062 (vosilasarm), a first-in-class oral selective androgen receptor modulator (SARM), in combination with standard-of-care endocrine therapy +/- targeted therapies in patients with advanced or metastatic AR+/ER+/HER2− breast cancer.

Rafael Grochot, J O'Shaughnessy, Meritxell Bellet et al.|Journal of Clinical Oncology|2026

Cited by 0